SOURCE: CLX Investment Company, Inc.

December 19, 2006 09:00 ET

CLX Investment Company Announces Improvements to Zonda's HandiLab Testing Procedure

TEMECULA, CA -- (MARKET WIRE) -- December 19, 2006 -- CLX Investment Company, Inc. (OTCBB: CLXN), a diversified investment fund, today announced that portfolio investment Zonda, Incorporated has modified the testing procedure for its HandiLab line of medial diagnostic tests for the purpose of making the test easier to perform and allow for better interpretation of the end result.

The changes involve steps 4-6 of the former HandiLab product insert where Fluid B was added to the swab bud. Some users had reported difficulty pushing the swab through the foil barrier or the bud was left soaking in the fluid. Sometimes the fluid dripped past the foil membrane and pooled above the membrane when the device was turned cap side up.

In the new product insert, which can be viewed on Zonda Incorporated's corporate website at, indicates the new method to introduce Fluid B to the tip of the swab. The new step 5 eliminates the struggling to push the swab through the membrane, and keeps all excess fluid below the tip of the swab. Visibility through the plastic to read the result is much better, and therefore, interpretation is easier.

"Zonda Incorporated constantly strives to supplement and improve on its diagnostic products, and we are pleased to have instituted the improvements to the HandiLab testing procedure," stated Laurie J. Oleksiewicz, president of Zonda, Incorporated. "We appreciate any comments we receive from our customers and distributors, even if they are in the form of a complaint, as it helps us better understand the real world use of our products and institute improvements to future versions of our tests."

To sign up to receive information by email directly from CLX Investment Company when new press releases, investor newsletters, SEC filings, or other information is disclosed, please visit

About Zonda, Incorporated

Zonda, Inc. (, in which CLX holds a 31% equity interest, specializes in diagnostic tests that serve the medical, food safety, cosmetic, beverage, pharmaceutical, veterinary, and environmental sanitation testing markets. Zonda's product line includes innovative, rapid, self-contained diagnostic devices for the detection of chlamydia, gonorrhea, yeast (Candida albicans) and Group A Strep, tests that detect bacterial and other potential harmful micro-organisms on surfaces, and confirmation tests for a wide variety of bacteria. Each of the Zonda infectious disease tests are marketed as superior to their competition due to their comparable accuracy (compared directly to PCR or DNA testing), ease of use, compact design, long shelf life, rapid results, and cost effectiveness.

About CLX Investment Company

CLX Investment Company ( holds a 31% equity interest in Zonda, Inc. ( CLX has also invested, and holds a common stock position, in ActionView International, Inc. (, a publicly traded global manufacturer and marketer of "smart" scrolling advertising billboards.

CLX has elected to be regulated as a Business Development Company pursuant to Section 54 of the Investment Company Act of 1940, and is pursuing a business plan wherein the Company seeks to make investment in developing companies with the goal of providing return for its shareholders.

All statements included in this release, including statements regarding potential future plans and objectives of CLX Investments are forward-looking statements. Such statements are necessarily subject to risks and uncertainties, some of which are significant in scope and nature beyond CLX Investments' control. There can be no assurance that such statements will prove accurate. Actual results and future events could differ materially from those anticipated in such statements depending on many factors. Historical results are not necessarily indicative of future performance.

Contact Information

  • Contact:
    Gemini Financial Communications
    A. Beyer
    Email Contact